CRISPR-Cas12a Gene Editing of <i>HBG1</i> and <i>HBG2</i> Promoters to Treat Sickle Cell Disease

Rabi Hanna

Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland

Haydar Frangoul

Sarah Cannon Research Institute at the Children’s Hospital at TriStar Centennial, Nashville

Luis Pineiro

Blood and Marrow Transplant Program and Marrow Processing Laboratory, Baylor University Medical Center, Dallas

Christopher McKinney

Department of Pediatrics, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora

Markus Mapara

Bone Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York

Jignesh Dalal

Rainbow Babies and Children’s Hospital, Cleveland

Hemalatha G. Rangarajan

Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Nationwide Children’s Hospital, Columbus, OH

Harold Atkins

Transplant and Cell Therapy Program, Department of Medicine, Ottawa Hospital, Ottawa

Akshay Sharma

Kai-Hsin Chang

Department of Chemistry

Michael C. Jaskolka

Editas Medicine, Cambridge, MA

Keunpyo Kim

Editas Medicine, Cambridge, MA

Qifeng Yu

Baisong Mei

Editas Medicine, Cambridge, MA

Olubunmi Afonja

Editas Medicine, Cambridge, MA

Mark C. Walters

UCSF Benioff Children’s Hospital, Oakland, CA